Indole-based Therapeutics for Patients with Pulmonary NTM Infection

Opportunity

Available for Licensing

IP Status

US Utility Patent: US 10383848 B2

Inventors

Mary C Jackson
Jeffrey North

At A Glance

Researchers at Colorado State University in collaboration with Creighton patented novel indole-2-carboxamide compounds for the treatment of non-tuberculous mycobacterial (NTM) infections.  The development of these narrow-spectrum anti-mycobacterial drugs could revolutionize the treatment of NTM.

Licensing Director

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.:  16-102

Background

Non-tuberculous mycobacteria (NTM) are opportunistic pathogens, where the prevalence of NTM pulmonary infections in the United States and globally is increasing.  Transmission of these pathogens may occur both from environmental sources and from person-to-person.  The Mycobacterium avium complex (MAC) and Mycobacterium abscessus complex (MABSC) account for the vast majority (70-95%) of global pulmonary NTM infections.  While MAC is still, overall, the most common cause of NTM infections in the US (accounting for over 70% of NTM pulmonary infections), over the last 10 years, rapidly-growing NTM of the M. abscessus complex (including the subspecies M. abscessus, M. massiliense and M. bolletii) have emerged as important human pathogens globally, causing an increasing number of pulmonary infections, especially  among patients with structural lung disease such as chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis (CF).

MABSC species cause serious, life-threatening, chronic lung disease, are responsible for disseminated, often fatal, infections following lung transplantation and are associated with a higher fatality rate than any other rapidly growing mycobacteria.  Of growing concern is the report that the prevalence of MABSC infections is becoming higher than that of MAC infections in CF patients worldwide, and that MABSC infections tend to target the younger CF population and those with more severe lung disease.  Prevalence rates of MABSC infections among children and adult CF patients range from 5% to 48%. MABSC infection in CF patients is particularly problematic as it results in accelerated inflammatory lung damage, can be impossible to treat (with 60-70% treatment failures despite years of combination therapy), and precludes lung transplantation in many US and European centers.

MABSC species are indeed not only the most pathogenic rapidly growing mycobacteria, they are also the most antibiotic-resistant NTM.  There are many factors that contribute to the drug resistance or drug tolerance of these microorganisms and as a result, the 2007 American Thoracic Society treatment guidelines cite no proven regimens to treat M. abscessus pulmonary infections.  Current treatment recommendations include multidrug therapy with combinations of intravenous and oral antibiotics accompanied, in some cases, by surgical resection.  Furthermore, most likely reflecting a defect in primary lung defense mechanisms, MABSC strains responsible for lung infections tend to co-occur with other pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.

Benefits
  • Indole-based compounds are mycobacteria-specific
  • Animals models indicate efficacy against intrinsically drug resistant non-tuberculous mycobacteria
Publications

Franz, Nicholas D, et al. “Design, Synthesis and Evaluation of Indole-2-Carboxamides with Pan Anti-Mycobacterial Activity.” Bioorganic & Medicinal Chemistry, U.S. National Library of Medicine, 15 July 2017, www.ncbi.nlm.nih.gov/pubmed/28545813.

Last updated: March 2020

Add keywords or various names of inventors here (text is hidden)